New hope for kids with rare cell disease: targeted pill tested
NCT ID NCT06582745
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a targeted drug called trametinib in 75 children with Langerhans cell histiocytosis (LCH), a rare disease where immune cells grow out of control. The goal is to see if the drug can safely stop the disease from getting worse or coming back. Children with new, relapsed, or hard-to-treat LCH may join.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cook Children's Health Care System
RECRUITINGFort Worth, Texas, 76104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive study tracks hidden toll of rare immune diseases
- Rare disease study probes hidden brain effects
- New hope for kids with rare immune disorder: international trial tests drug cocktails
- Robot buddies let kids with cancer attend class from hospital bed
- New PET tracer could spot Hard-to-See cancers
- Massive childhood cancer registry launches to unlock secrets of the disease